Safety of new tuberculosis treatment regimens and compliance with these regimens according to data from the Republic of Kazakhstan

Abstract

The objective: to assess the safety and compliance with new regimens for preventive treatment of drug susceptible and drug resistant tuberculosis.Subjects and Methods. The study was carried out in Almaty, the Republic of Kazakhstan; 182 patients from the groups facing the high risk of developing active tuberculosis received preventive tuberculosis treatment with new regimens: 71 patients were treated with isoniazid and rifampicin for 3 months (3 HR), 55 - with isoniazid and rifapentine for 1 month (1 HR), 56 - with levofloxacin for 6 months (6 Lfx).Results. During treatment with regimens 3 HR, 1 HP, 6 Lfx, no adverse events of severity degree 3-4 developed , while adverse events of severity degree 1-2 were rare and relieved. The patient-oriented approach to the organization of preventive chemotherapy made it possible to achieve high treatment completion rates: in the group receiving 3 HR, it was 97.2% of cases, in the group receiving 1 HP - 96.4%, and in the group receiving 6 Lfx - 82.2%.